FDAnews Device Daily Bulletin

ANGIOTECH SIGNS GENZYME DEAL

May 11, 2006
A A

Angiotech Pharmaceuticals Inc., best known for its drug-coated stents, reported lower profits Tuesday but said it has signed a deal to develop cancer treatments with U.S. biotechnology company Genzyme (Nasdaq:GENZ).
Canoe Money